Market Scenario
Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era. Scope of the Report: In China, antitumor drugs are also the key areas of concern for many enterprises. Such as Jiangsu Hengrui, Qilu Pharmaceutical and other well-known domestic enterprises in the anti-tumor drugs have invested a lot of money, there are many innovative anti-cancer drugs into the clinical research stage. In the meantime, there has been "explosive" growth in the development of molecularly targeted drugs, with at least hundreds of drugs under development, and it is conceivable that the market will be quite crowded in the next five to 10 years. Therefore, domestic enterprises should fully understand the feasibility of the project and the fierce market competition that they may face in the future. China's bio-pharmaceutical industry already has a good foundation; from the national level to local governments at all levels continue to step up efforts to support the development of bio-pharmaceutical industry. The output value of the pharmaceutical industry maintained a growth rate of 20% during the 12th Five-Year Plan period. In 2013, the total output value of the pharmaceutical industry reached 2.1 trillion yuan. However, compared with the bio-pharmaceutical industry in the advanced countries in the world, there is still a huge gap between the biomedical industry in our country and the demand for building an overall well-to-do society. Mainly manifested in: small-scale enterprises, more than 10 billion yuan enterprises and more than one billion yuan less; independent innovation ability is weak, many varieties of imitation with independent intellectual property rights of the few species; restrict some of the long-term development of biomedical industry , Deep-seated problems still exist. The global Anti-tumor Drug market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions. North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Anti-tumor Drug. Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%. This report studies the Anti-tumor Drug market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Anti-tumor Drug market by product type and applications/end industries. Market Segment by Companies, this report covers Roche Novartis Celgene Bristol-Myers Squibb Amgen Johnson & Johnson Pfizer Takeda Eli Lilly AstraZeneca Astellas Merck & Co Sanofi Bayer Biogen Idec Eisai Teva Otsuka Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, Colombia) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Market Segment by Type, covers Cytotoxic Drugs Non-cytotoxic Drugs Market Segment by Applications, can be divided into Alkylating Agents Anti-metabolism Drugs Platinum Antineoplastic Agents Anthracycline antitumor drugs Microtubule Stabilizer Endocrine Therapy Drugs Immunotherapy Drugs Gene Therapy Drugs Targeted Antineoplastic Drugs
Table of Contents
Table of Contents 1 Anti-tumor Drug Market Overview 1.1 Product Overview and Scope of Anti-tumor Drug 1.2 Classification of Anti-tumor Drug by Types 1.2.1 Global Anti-tumor Drug Revenue Comparison by Types (2019-2024) 1.2.2 Global Anti-tumor Drug Revenue Market Share by Types in 2018 1.2.3 Cytotoxic Drugs 1.2.4 Non-cytotoxic Drugs 1.3 Global Anti-tumor Drug Market by Application 1.3.1 Global Anti-tumor Drug Market Size and Market Share Comparison by Applications (2014-2024) 1.3.2 Alkylating Agents 1.3.3 Anti-metabolism Drugs 1.3.4 Platinum Antineoplastic Agents 1.3.5 Anthracycline antitumor drugs 1.3.6 Microtubule Stabilizer 1.3.7 Endocrine Therapy Drugs 1.3.8 Immunotherapy Drugs 1.3.9 Gene Therapy Drugs 1.3.10 Targeted Antineoplastic Drugs 1.4 Global Anti-tumor Drug Market by Regions 1.4.1 Global Anti-tumor Drug Market Size (Million USD) Comparison by Regions (2014-2024) 1.4.1 North America (USA, Canada and Mexico) Anti-tumor Drug Status and Prospect (2014-2024) 1.4.2 Europe (Germany, France, UK, Russia and Italy) Anti-tumor Drug Status and Prospect (2014-2024) 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Anti-tumor Drug Status and Prospect (2014-2024) 1.4.4 South America (Brazil, Argentina, Colombia) Anti-tumor Drug Status and Prospect (2014-2024) 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Anti-tumor Drug Status and Prospect (2014-2024) 1.5 Global Market Size of Anti-tumor Drug (2014-2024) 2 Manufacturers Profiles 2.1 Roche 2.1.1 Business Overview 2.1.2 Anti-tumor Drug Type and Applications 2.1.2.1 Product A 2.1.2.2 Product B 2.1.3 Roche Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 2.2 Novartis 2.2.1 Business Overview 2.2.2 Anti-tumor Drug Type and Applications 2.2.2.1 Product A 2.2.2.2 Product B 2.2.3 Novartis Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 2.3 Celgene 2.3.1 Business Overview 2.3.2 Anti-tumor Drug Type and Applications 2.3.2.1 Product A 2.3.2.2 Product B 2.3.3 Celgene Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 2.4 Bristol-Myers Squibb 2.4.1 Business Overview 2.4.2 Anti-tumor Drug Type and Applications 2.4.2.1 Product A 2.4.2.2 Product B 2.4.3 Bristol-Myers Squibb Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 2.5 Amgen 2.5.1 Business Overview 2.5.2 Anti-tumor Drug Type and Applications 2.5.2.1 Product A 2.5.2.2 Product B 2.5.3 Amgen Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 2.6 Johnson & Johnson 2.6.1 Business Overview 2.6.2 Anti-tumor Drug Type and Applications 2.6.2.1 Product A 2.6.2.2 Product B 2.6.3 Johnson & Johnson Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 2.7 Pfizer 2.7.1 Business Overview 2.7.2 Anti-tumor Drug Type and Applications 2.7.2.1 Product A 2.7.2.2 Product B 2.7.3 Pfizer Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 2.8 Takeda 2.8.1 Business Overview 2.8.2 Anti-tumor Drug Type and Applications 2.8.2.1 Product A 2.8.2.2 Product B 2.8.3 Takeda Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 2.9 Eli Lilly 2.9.1 Business Overview 2.9.2 Anti-tumor Drug Type and Applications 2.9.2.1 Product A 2.9.2.2 Product B 2.9.3 Eli Lilly Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 2.10 AstraZeneca 2.10.1 Business Overview 2.10.2 Anti-tumor Drug Type and Applications 2.10.2.1 Product A 2.10.2.2 Product B 2.10.3 AstraZeneca Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 2.11 Astellas 2.11.1 Business Overview 2.11.2 Anti-tumor Drug Type and Applications 2.11.2.1 Product A 2.11.2.2 Product B 2.11.3 Astellas Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 2.12 Merck & Co 2.12.1 Business Overview 2.12.2 Anti-tumor Drug Type and Applications 2.12.2.1 Product A 2.12.2.2 Product B 2.12.3 Merck & Co Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 2.13 Sanofi 2.13.1 Business Overview 2.13.2 Anti-tumor Drug Type and Applications 2.13.2.1 Product A 2.13.2.2 Product B 2.13.3 Sanofi Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 2.14 Bayer 2.14.1 Business Overview 2.14.2 Anti-tumor Drug Type and Applications 2.14.2.1 Product A 2.14.2.2 Product B 2.14.3 Bayer Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 2.15 Biogen Idec 2.15.1 Business Overview 2.15.2 Anti-tumor Drug Type and Applications 2.15.2.1 Product A 2.15.2.2 Product B 2.15.3 Biogen Idec Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 2.16 Eisai 2.16.1 Business Overview 2.16.2 Anti-tumor Drug Type and Applications 2.16.2.1 Product A 2.16.2.2 Product B 2.16.3 Eisai Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 2.17 Teva 2.17.1 Business Overview 2.17.2 Anti-tumor Drug Type and Applications 2.17.2.1 Product A 2.17.2.2 Product B 2.17.3 Teva Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 2.18 Otsuka 2.18.1 Business Overview 2.18.2 Anti-tumor Drug Type and Applications 2.18.2.1 Product A 2.18.2.2 Product B 2.18.3 Otsuka Anti-tumor Drug Revenue, Gross Margin and Market Share (2017-2018) 3 Global Anti-tumor Drug Market Competition, by Players 3.1 Global Anti-tumor Drug Revenue and Share by Players (2014-2019) 3.2 Market Concentration Rate 3.2.1 Top 5 Anti-tumor Drug Players Market Share 3.2.2 Top 10 Anti-tumor Drug Players Market Share 3.3 Market Competition Trend 4 Global Anti-tumor Drug Market Size by Regions 4.1 Global Anti-tumor Drug Revenue and Market Share by Regions 4.2 North America Anti-tumor Drug Revenue and Growth Rate (2014-2019) 4.3 Europe Anti-tumor Drug Revenue and Growth Rate (2014-2019) 4.4 Asia-Pacific Anti-tumor Drug Revenue and Growth Rate (2014-2019) 4.5 South America Anti-tumor Drug Revenue and Growth Rate (2014-2019) 4.6 Middle East and Africa Anti-tumor Drug Revenue and Growth Rate (2014-2019) 5 North America Anti-tumor Drug Revenue by Countries 5.1 North America Anti-tumor Drug Revenue by Countries (2014-2019) 5.2 USA Anti-tumor Drug Revenue and Growth Rate (2014-2019) 5.3 Canada Anti-tumor Drug Revenue and Growth Rate (2014-2019) 5.4 Mexico Anti-tumor Drug Revenue and Growth Rate (2014-2019) 6 Europe Anti-tumor Drug Revenue by Countries 6.1 Europe Anti-tumor Drug Revenue by Countries (2014-2019) 6.2 Germany Anti-tumor Drug Revenue and Growth Rate (2014-2019) 6.3 UK Anti-tumor Drug Revenue and Growth Rate (2014-2019) 6.4 France Anti-tumor Drug Revenue and Growth Rate (2014-2019) 6.5 Russia Anti-tumor Drug Revenue and Growth Rate (2014-2019) 6.6 Italy Anti-tumor Drug Revenue and Growth Rate (2014-2019) 7 Asia-Pacific Anti-tumor Drug Revenue by Countries 7.1 Asia-Pacific Anti-tumor Drug Revenue by Countries (2014-2019) 7.2 China Anti-tumor Drug Revenue and Growth Rate (2014-2019) 7.3 Japan Anti-tumor Drug Revenue and Growth Rate (2014-2019) 7.4 Korea Anti-tumor Drug Revenue and Growth Rate (2014-2019) 7.5 India Anti-tumor Drug Revenue and Growth Rate (2014-2019) 7.6 Southeast Asia Anti-tumor Drug Revenue and Growth Rate (2014-2019) 8 South America Anti-tumor Drug Revenue by Countries 8.1 South America Anti-tumor Drug Revenue by Countries (2014-2019) 8.2 Brazil Anti-tumor Drug Revenue and Growth Rate (2014-2019) 8.3 Argentina Anti-tumor Drug Revenue and Growth Rate (2014-2019) 8.4 Colombia Anti-tumor Drug Revenue and Growth Rate (2014-2019) 9 Middle East and Africa Revenue Anti-tumor Drug by Countries 9.1 Middle East and Africa Anti-tumor Drug Revenue by Countries (2014-2019) 9.2 Saudi Arabia Anti-tumor Drug Revenue and Growth Rate (2014-2019) 9.3 UAE Anti-tumor Drug Revenue and Growth Rate (2014-2019) 9.4 Egypt Anti-tumor Drug Revenue and Growth Rate (2014-2019) 9.5 Nigeria Anti-tumor Drug Revenue and Growth Rate (2014-2019) 9.6 South Africa Anti-tumor Drug Revenue and Growth Rate (2014-2019) 10 Global Anti-tumor Drug Market Segment by Type 10.1 Global Anti-tumor Drug Revenue and Market Share by Type (2014-2019) 10.2 Global Anti-tumor Drug Market Forecast by Type (2019-2024) 10.3 Cytotoxic Drugs Revenue Growth Rate (2014-2024) 10.4 Non-cytotoxic Drugs Revenue Growth Rate (2014-2024) 11 Global Anti-tumor Drug Market Segment by Application 11.1 Global Anti-tumor Drug Revenue Market Share by Application (2014-2019) 11.2 Anti-tumor Drug Market Forecast by Application (2019-2024) 11.3 Alkylating Agents Revenue Growth (2014-2019) 11.4 Anti-metabolism Drugs Revenue Growth (2014-2019) 11.5 Platinum Antineoplastic Agents Revenue Growth (2014-2019) 11.6 Anthracycline antitumor drugs Revenue Growth (2014-2019) 11.7 Microtubule Stabilizer Revenue Growth (2014-2019) 11.8 Endocrine Therapy Drugs Revenue Growth (2014-2019) 11.9 Immunotherapy Drugs Revenue Growth (2014-2019) 11.10 Gene Therapy Drugs Revenue Growth (2014-2019) 11.11 Targeted Antineoplastic Drugs Revenue Growth (2014-2019) 12 Global Anti-tumor Drug Market Size Forecast (2019-2024) 12.1 Global Anti-tumor Drug Market Size Forecast (2019-2024) 12.2 Global Anti-tumor Drug Market Forecast by Regions (2019-2024) 12.3 North America Anti-tumor Drug Revenue Market Forecast (2019-2024) 12.4 Europe Anti-tumor Drug Revenue Market Forecast (2019-2024) 12.5 Asia-Pacific Anti-tumor Drug Revenue Market Forecast (2019-2024) 12.6 South America Anti-tumor Drug Revenue Market Forecast (2019-2024) 12.7 Middle East and Africa Anti-tumor Drug Revenue Market Forecast (2019-2024) 13 Research Findings and Conclusion 14 Appendix 14.1 Methodology 14.2 Data Source
Methodology
This research report involves complete picture of the market with the help of in-depth secondary and primary research. This research report studies several aspects of the market and analyze vital industry influencers. Extensive secondary research has been conducted using paid as well as open access data sources in order to gather information on the market and parent market. These key findings are then analyzed and validated with the help of in-house data models and primary discussions with key industry participants and experts across the value chain
Research Tools and Models
- Top-Down Approach and Bottom-Up Approach
- QFD Modeling for Market Size and Share Calculation
- Regression, Variable and Impact Analysis
- Penetration Modeling
Qualitative Research
- It comprises briefing about market dynamics and business opportunities and strategies.
- Finally, all the research findings are validated through interviews with in-house industry experts, freelance consultants and key opinion leaders etc.
Quantitative Research
It involves various mathematical tools, models, projection, and sampling techniques. It involves following steps:
- Identification of market variables and market size derivation
- Assessment of future prospects, opportunities and market penetration rates by analyzing product commercialization, regional trends etc.
- Evaluation historical market trends and derivation of present and future year-on-year growth trends
